REGENXBIO closes strategic partnership with Nippon Shinyaku for MPS gene therapies

REGENXBIO Inc.

Partnership closed for development/commercialization of RGX-121 (MPS II) and RGX-111 (MPS I) in US and Asia.
RGX-121 on track as first gene therapy for MPS II; potential FDA approval as early as late 2025.
CEO Curran Simpson highlights transformative potential for MPS patient populations.
No financial terms disclosed in this filing; partnership was previously announced.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.